Diagnostics & imaging AI · Stroke imaging AI
Methinks AI
Methinks AI makes stroke software that detects suspected large vessel occlusions and brain bleeds on non-contrast CT, plus an FDA-cleared CT angiography tool, with alerts in Microsoft Teams.
Strong fit
- Hospitals that see stroke patients but usually have only a non-contrast CT scanner available
- Networks that run stroke coordination in Microsoft Teams
- Stroke programs in Europe, the Middle East, and Africa looking for a tool with Medtronic distribution
Weak fit
- Comprehensive stroke centers that need full perfusion imaging
- Buyers who want a long list of published U.S. outcome studies
- Buyers who need a published price list
Bottom line
Methinks AI is a Barcelona, Spain company whose software looks for blocked brain arteries and brain bleeds on non-contrast CT, the basic scan almost every hospital can do. It also has an FDA-cleared tool for CT angiography, and it sends results to stroke teams inside Microsoft Teams. It is a Conditional pick because it is early in U.S. sales and has fewer published results than older stroke imaging vendors.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
Cristian Martí founded Methinks in Barcelona in 2016, after selling his GPS vehicle tracking company Coordina to TomTom in 2013. Pau Rodríguez joined as chief executive. Methinks NCCT Stroke reads the non-contrast CT scan that most stroke patients get first and flags suspected large vessel occlusions and brain bleeds, a scan almost any hospital can perform. The company says it was the first CE-marked device to detect large vessel occlusions on non-contrast CT. Results reach the stroke team through Microsoft Teams, and the software runs in the cloud.
Methinks NCCT Stroke received FDA 510(k) clearance in July 2025. The company says FDA validation studies showed it missed nearly 50 percent fewer suspected occlusions than the most accurate other non-contrast CT tool. In October 2025 Methinks CTA Stroke received a second clearance, with reported sensitivity of 98.2 percent and specificity of 91.6 percent. In March 2025 Medtronic signed a partnership to bring Methinks to hospitals in Central and Eastern Europe, Africa, Türkiye, and the Middle East.
Compare RapidAI when a stroke center needs CT perfusion and a broad platform, Brainomix when a network wants large real-world outcome studies, Viz.ai when care team coordination across many hospitals is the main job, and Nicolab when a network wants imaging AI and collaboration tools from one vendor.
Competitor landscape
| Vendor | Overall | Ease of implementation |
|---|---|---|
| RapidAI | 8.1 | 7.6 |
| Brainomix | 7.8 | 7.7 |
| Viz.ai | 7.7 | 7.3 |
| Nicolab | 7.3 | 7.3 |
| Methinks AI | 6.8 | 7.0 |
Pricing
| Item | Detail |
|---|---|
| Model | Subscription quoted by Methinks or its distribution partners. It is also listed on the Microsoft Azure Marketplace. |
| What usually drives cost | Number of hospitals, which tools are used (non-contrast CT, CT angiography), and whether the Teams integration is included. |
| What to ask in diligence | Annual price per hospital, what Medtronic or other partners add, and whether a pilot price converts to a full contract. |
| Published pricing | No public list price. |
Prerequisites for purchase
| Need | Why it matters |
|---|---|
| What you need to get Methinks AI to function | |
| Stroke lead at each hospital | Alerts need a clinician who acts on them. |
| CT connection to the cloud service | Scans must reach Methinks within minutes. |
| Microsoft Teams set up for the stroke team | Results are delivered there. |
| Transfer agreement with a thrombectomy center | Finding a blocked artery only helps if the patient can be moved. |
| Security and data protection review | Images are processed in the cloud. |
| What will maximize your value | |
| Start at hospitals without round-the-clock CT angiography | That is where non-contrast CT detection adds most. |
| Track transfer times before and after | Shows whether alerts speed treatment. |
| Add CT angiography analysis where it is available | Two reads give the team more confidence. |
| Deal-breakers | |
| No transfer partner | |
| No Teams environment | |
| Needs perfusion imaging | |
Value creation time frame
| # | Stage | Typical range |
|---|---|---|
| 1 | Contract and security review | 3-6 weeks |
| 2 | First hospital live | 2-6 weeks |
| 3 | Network expansion | 2-6 months |
Leadership
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.